Streetbeat News

CMPS

COMPASS Pathways plc

Industry

Medical - Care Facilities

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Open

5.15

Mkt cap

345M

Volume

3.6M

High

6.04

P/E Ratio

-2.31

52-wk high

12.75

Low

4.97

Div yield

N/A

52-wk low

4.05

Several studies and trials are set to assess the use of psilocybin-assisted therapy for various addictions and pain management. Former NHL player Kyle Quincey is building a psilocybin-assisted therapy center in Colorado. GH Research, Cybin, Enveric Biosciences, Red Light Holland, Incannex Healthcare, and Sunstone Therapies have made significant advancements in their respective programs. The AdvisorShares Psychedelics ETF has seen a consistent lowering trend in its price. GH Research, COMPASS Pathways, Mind Medicine, Bright Minds Biosciences, Enveric Biosciences, Silo Pharma, atai Life Sciences, Incannex Healthcare, FSD Pharma, and Seelos Therapeutics saw varied closing prices.

Portfolio Pulse from Lara Goldstein

August 28, 2023 | 8:07 pm

Compass Pathways (NASDAQ:CMPS) has received mostly bullish ratings from analysts in the last quarter, with 8 bullish, 3 somewhat bullish, and no bearish or indifferent ratings. The average 12-month price target for the stock is $56.82, representing a 5.3% decrease from the previous average of $60.00.

Portfolio Pulse from Benzinga Insights

August 22, 2023 | 2:00 pm

Cantor Fitzgerald analyst Jonathan Fiore has reiterated an Overweight rating on Compass Pathways (NASDAQ:CMPS) and maintained a $21 price target.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 1:22 pm

Canaccord Genuity analyst Sumant Kulkarni maintains a 'Buy' rating on Compass Pathways (NASDAQ:CMPS) but lowers the price target from $60 to $50.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 1:15 pm

A recent study by the Federal Reserve indicates that cannabis and psychedelics consumption has reached all-time highs in 2022, particularly among adults aged 35-50. In other news, COMPASS Pathways (NASDAQ:CMPS) has entered into a securities purchase agreement for an initial $125 million and a potential additional $160 million, while MindMed (NASDAQ:MNMD) has secured a $50 million senior secured credit facility with K2 HealthVentures. The AdvisorShares Psychedelics ETF (NYSE:PSIL) opened at $1.8 on August 14, slightly below prior openings.

Portfolio Pulse from Lara Goldstein

August 21, 2023 | 2:55 pm

Cresco Labs released Q2 2023 results with a revenue of $198m, up 2% sequentially, and an adjusted EBITA stock rise to $40.9m. Columbia Care's Q2 revenues fell slightly to $129m. COMPASS Pathways announced a securities purchase agreement that could secure most of the funding for their ongoing Phase 3 psilocybin-assisted clinical therapy trial. The agreement entails the issuance of 16,076,750 American Depositary Shares and equivalent number of purchase warrants, potentially bringing in approximately $125m directly to COMPASS.

Portfolio Pulse from The Dales Report

August 18, 2023 | 5:20 pm

Cantor Fitzgerald analyst Jonathan Fiore has reiterated an Overweight rating on Compass Pathways (NASDAQ:CMPS) and maintained a $21 price target.

Portfolio Pulse from richadhand@benzinga.com

August 17, 2023 | 3:49 pm

COMPASS Pathways has announced a private placement of 16,076,750 shares at $7.78 per share, raising $285 million. This has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 4:29 pm

Psychedelics biotech company COMPASS Pathways (NASDAQ:CMPS) has secured a securities purchase agreement for an initial $125 million and potential additional of $160 million, backed by a group of healthcare specialist investors led by TCGX and Aisling Capital. The agreement includes the private placement of over 16 million American Depositary Shares (ADS) and warrants to purchase up to the same amount of ADSs. The financing is expected to close on August 18, extending the company's cash runway into late 2025.

Portfolio Pulse from Lara Goldstein

August 16, 2023 | 2:47 pm

COMPASS Pathways has announced a private placement of 16,076,750 shares at $7.78 per share, which could raise up to $285 million.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 1:01 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.